Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 8/20 | 0.49 |
| ▸ | AURKA | O14965 | 8/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402715 | 0.89 | MET (0.60) | AURKBAURKAMETSRCKDR | |
| SCHEMBL5402679 | 0.84 | AURKB (0.57) | AURKBAURKAMETSRCKDR | |
| SCHEMBL5403331 | 0.83 | MET (0.67) | AURKBAURKAMETSRCKDR | |
| SCHEMBL5396553 | 0.79 | AKR1C3 (0.48) | AURKBAURKAMETSRCKDR | |
| SCHEMBL3794503 | 0.79 | MEN1 (0.62) | SRCKDRPDGFRBFGFR1MEN1 | |
| SCHEMBL3794502 | 0.79 | MEN1 (0.62) | SRCKDRPDGFRBFGFR1MEN1 | |
| SCHEMBL5405471 | 0.78 | MET (0.72) | AURKBAURKAMETSRCKDR | |
| SCHEMBL5406649 | 0.77 | MET (0.83) | AURKBAURKAMETSRCKDR | |
| SCHEMBL6216878 | 0.75 | CDK2 (0.68) | AURKBAURKAMETSRCKDR | |
| SCHEMBL6216879 | 0.75 | CDK2 (0.68) | AURKBAURKAMETSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | AURKB 414/4885AURKA 463/4885MET 2590/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | AURKB 125/4885AURKA 78/4885MET 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.